LRRC75A and neoplasm: Based on this evaluation, LINC00877 (Figure 8A), SLC25A5-AS1 (Figure 8B), ILF3-DT (Figure 8C), LRRC75A-AS1 (Figure 8D), LINC00324 (Figure 8E), CD27-AS1 (Figure 8F), ZFAS1 (Figure 8G), SNHG5 (Figure 8H), MIR762HG (Figure 8I), and SNRK-AS1 (Figure 8J) were the top significantly downregulated tumor suppressor candidates in MCL cases.